ライフサイエンスコーパス: epsilon-aminocaproic acid

1 intravenous iron, erythropoietin, G-CSF, and epsilon aminocaproic acid.

2 TIP49a protein, and binding was inhibited by epsilon-aminocaproic acid.

3 d in the absence and presence of the ligand, epsilon-aminocaproic acid.

4 This process is inhibited by epsilon-aminocaproic acid.

5 This force can be reduced by the presence of epsilon-aminocaproic acid.

6 gnificant reduction in total blood loss over epsilon-aminocaproic acid (-184 mL; 95% CI, -256 to -112

7 ons in total postoperative transfusions with epsilon-aminocaproic acid (61% reduction versus placebo,

8 4-aminobutyric acid, 5-aminopentanoic acid, epsilon-aminocaproic acid, 7-aminoheptanoic acid, and t-

9 epsilon-Aminocaproic acid, a Lys analogue, effectively b

10 tibodies directed against t-PA and u-PA, and epsilon-aminocaproic acid, a lysine analog that inhibits

11 none of the reductions in IL-6 and IL-10 by epsilon-aminocaproic acid achieved statistical significa

12 n and other animal plasma in the presence of epsilon -aminocaproic acid, an active-site inhibitor tha

13 toperative hemorrhage after cardiac surgery, epsilon-aminocaproic acid, an alternative antifibrinolyt

14 epsilon-Aminocaproic acid and aprotinin had no effect on

15 Both the lysine analog epsilon-aminocaproic acid and L-proline inhibited the bi

16 stantial reductions in total blood loss with epsilon-aminocaproic acid and low-dose aprotinin (each w

17 Fibrinolysis inhibitors, including epsilon-aminocaproic acid and tranexamic acid, were effe

18 ducted a meta-analysis to compare aprotinin, epsilon-aminocaproic acid, and tranexamic acid with plac

19 Aprotinin but not epsilon-aminocaproic acid appears to attenuate the rise

20 ex concentrate, recombinant factor VIIa, and epsilon-aminocaproic acid, as potential therapeutic opti

21 ment of mice with the fibrinolytic inhibitor epsilon-aminocaproic acid before endotoxin increased bot

22 The plasminogen-specific inhibitor epsilon-aminocaproic acid blocked the tv-rENO1-plasminog

23 nti-HPRG antiserum, by low concentrations of epsilon-aminocaproic acid, by methylation of lysine resi

24 Both aprotinin and epsilon-aminocaproic acid decreased blood loss compared

25 These data suggest that aprotinin and epsilon-aminocaproic acid differ in their effects on the

26 of human plasminogen (Klpg) with the ligands epsilon-aminocaproic acid (EACA) and trans-4-(aminomethy

27 fibrinolytic drugs tranexamic acid (TXA) and epsilon-aminocaproic acid (EACA) are structurally simila

28 The binding constants of epsilon-aminocaproic acid (EACA), 7-aminoheptanoic acid

29 that inhibited plasminogen activation, e.g., epsilon-aminocaproic acid (EACA), or plasminogen antiser

30 and is inhibited by lysine analogues such as epsilon-aminocaproic acid (EACA).

31 (M66 variant) in its unliganded and ligand [epsilon-aminocaproic acid (EACA)] bound modes and the st

32 The binding is inhibited by epsilon-aminocaproic acid (epsilonACA), indicating the r

33 In contrast, epsilon-aminocaproic acid, fibrin, and fibrinogen, which

34 Antifibrinolytic drugs such as aprotinin and epsilon-aminocaproic acid have been effective in reducin

35 ell adhesion inasmuch as tranexamic acid and epsilon-aminocaproic acid inhibited cell adhesion.

36 inogen, and the presence of a lysine analog, epsilon-aminocaproic acid, inhibited the ErpP-plasminoge

37 efficacies, the considerably less-expensive epsilon-aminocaproic acid may be preferred over aprotini

38 d between 1985 and 1998 involving the use of epsilon-aminocaproic acid (n=9) or aprotinin (n=46) in p

39 study examined the effects of aprotinin and epsilon-aminocaproic acid on plasma levels of proinflamm

40 The presence of epsilon-aminocaproic acid only slightly inhibited bindin

41 tients transfused was similarly reduced with epsilon-aminocaproic acid (OR, 0.32; 95% CI, 0.15 to 0.6

42 -blind study to receive high-dose aprotinin, epsilon-aminocaproic acid, or saline placebo.

43 Saturating levels of epsilon-aminocaproic acid reduced the affinity of SK for

44 ed TAFIa from human serum in the presence of epsilon -aminocaproic acid was also developed.

45 yclo(Phe-4-Cpa-Gln-D-Phe-Pro-Asp-Aca) (Aca = epsilon-aminocaproic acid), which did not contain tyrosi

46 nducted in the presence of the lysine analog epsilon-aminocaproic acid, which precludes apo(a)-B100 a